Abstract
Objectives: To determine the outcome of patients with a serum prostate-specific antigen (PSA) level >20 ng/ml that underwent radical prostatectomy (RP).
Methods: We retrospectively reviewed the medical records of 147 patients who underwent RP for clinically localized prostate cancer with a pre-treatment PSA (PSApt) >20 ng/ml. Fifty-two patients had positive pelvic lymph nodes and were excluded from analysis. Of 95 patients remaining, 15 were lost to follow-up. Therefore, the study group included 80 patients. The end points for this analysis were biochemical relapse-free survival (bRFS), surgical and post-operative complications and urinary continence. PSApt, pathological grade, surgical margin status, age, clinical stage and immediate androgen ablation were evaluated in a multivariate analysis regarding bRFS.
Results: Forty-nine resected specimens (61.2%) were pathologically classified as pT3 or pT4. After a mean follow-up of 64 months, the estimated 5-year bRFS rate was 58% for the overall group. Immediate androgen ablation was the only independent prognostic factor for biochemical relapse (P=0.001). Concerning the 21 patients who received an immediate androgen ablation after RP, the estimated 5-year bRFS rate was 92%. Complete urinary continence was achieved in 76.5% of patients. Early complications occurred in 13 patients (16.2%).
Conclusions: Clinically localized prostate cancer with a PSApt >20 ng/ml is considered as having a poor prognosis. However, RP performed in these patients led to an acceptable morbidity and good functional results. Immediate adjuvant hormonal therapy seems mandatory in this setting to improve bRFS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bostwick DG, Qian J, Bergstrahl E . Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 1996; 155: 1361–1367.
Partin AW, Yoo J, Carter B, Pearson JD, Chan DW, Epstein JI et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110–114.
Kupelian PA, Katcher J, Levin HS, Klein EA . Stage T1–2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997; 37: 1043–1052.
D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH . Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol 2003; 169: 1320–1324.
D'Amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, Schultz D et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001; 166: 2185–2188.
Zagars GK, Pollack A, von Eschenbach AC . Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer 1997; 80: 764–775.
Partin AW, Mohler JL, Piantadosi S, Brendler CB, Sanda MG, Walsh PC et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995; 45: 831–838.
Anderson PR, Hanlon AL, Movsas B, Hanks GE . Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation. Int J Radiat Oncol Biol Phys 1997; 39: 1025–1030.
Kupelian P, Katcher J, Levin H, Zippe C, Klein E . Correlation of clinical and pathological factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996; 48: 249–260.
Freedland SJ, Sutter ME, Dorey F, Aronson WJ . Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003; 61: 365–369.
Hautmann RE, Sauter TW, Wenderoth UK . Radical retropubic prostatectomy: morbidity and urinary continence in 418 consecutive cases. Urology 1994; 43: 47–51.
Stein A, deKernion JB, Smith RB, Dorey F, Patel H . Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol 1992; 147: 942–946.
Ritchie AW, James K, deKernion JB . Early post-operative morbidity of total prostatectomy. Br J Urol 1989; 64: 511–515.
Leandri P, Rossignol G, Gautier JR, Ramon J . Radical retropubic prostatectomy : morbidity and quality of life. Experience with 620 consecutive cases. J Urol 1992; 147: 883–887.
Catalona WJ, Carvalhal GF, Mager DE, Smith DS . Potency, continence and complications rates in 1870 consecutive radical retropubic prostatectomies. J Urol 1999; 162: 433–438.
Donellan SM, Duncan HJ, MacGregor RJ, Russell JM . Prospective assessment of incontinence after radical retropubic prostatectomy: objective and subjective analysis. Urology 1997; 49: 225–230.
Walsh PC . Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol 2000; 163: 1802–1807.
D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995; 154: 131–138.
Brandli DW, Koch MO, Foster RS, Bihrle R, Gardner TA . Biochemical disease-free survival in patients with a high prostate-specific antigen level (20–100 ng/ml) and clinically localized prostate cancer after radical prostatectomy. BJU Int 2003; 92: 19–23.
Cheng L, Slezak J, Bergstralh EJ, Myers RP, Zincke H, Bostwick DG . Preoperative prediction of surgical margin status in patients with prostate cancer treated by radical prostatectomy. J Clin Oncol 2000; 18: 2862–2868.
Vanasupa BP, Paquette EL, Wu H, Sun L, McLeod DG, Moul JW . The role of radical prostatectomy in patients with pretreatment prostate-specific antigen ⩽40 ng/ml. Urol Oncol 2002; 7: 167–172.
Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K et al. Bicalutamide 150 mg in addition to standard care in patients with localized orlocally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004; 172: 1865–1870.
Collette L, van Poppel H, Bolla M, van Cangh P, Vekemans K, Da Pozzo L et al. Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). Eur J Cancer 2005; 41: 2662–2672.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bastide, C., Kuefer, R., Loeffler, M. et al. The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml. Prostate Cancer Prostatic Dis 9, 239–244 (2006). https://doi.org/10.1038/sj.pcan.4500892
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500892
Keywords
This article is cited by
-
Oncologic outcome after radical prostatectomy in men with PSA values above 20 ng/ml: a monocentric experience
World Journal of Urology (2009)